Background
Coronavirus disease 2019 (COVID-19), which first emerged in Wuhan in December 2019 and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread throughout China and has spread worldwide in the past three months. As of March 28, 2020, SARS-CoV-2 has spread to most regions of China, with more than 82 thousand confirmed infections, and has spread to at least 190 countries with more than 2.7 million infected individuals. The number of COVID-19 cases in children was described as very small [
1‐
3]. The data from the Chinese Centre for Disease Control and Prevention showed that out of 72,314 confirmed COVID-19 cases, there were 965 (1.3%) paediatric patients [
2], and in another study from the United States, 2572 (1.7%) paediatric patients were reported among 149,082 confirmed cases [
4]. However, with the continuous spread of SARS-CoV-2 worldwide, an increasing number of children will be infected in the future.
Recent studies have shown the primary features of paediatric patients with SARS-CoV-2 infection, and most paediatric cases appeared to be mild with symptoms of respiratory tract infection [
5‐
7]. It has been difficult for clinicians to distinguish COVID-19 from other various respiratory diseases based on the symptoms experienced by children. Respiratory virus infections, such as influenza infection, respiratory syncytial virus infection and rhinovirus infection, are very common diseases among children, especially in the winter season [
8]. Influenza was more common among children than adults, and 60% of patients were 18 years old or younger in the 2009 influenza pandemic [
9]. In China, children seldom receive flu vaccination. Recently, global influenza-associated mortality climbed to the highest level compared with that in any other flu season, and more than 240,000 influenza cases, including influenza A virus (53.5%) and influenza B virus (46.5%) infection, were laboratory confirmed in the United States in the past season [
10]. Hospitalization and mortality rates of influenza in children were higher than those previously reported [
10]. Because of the mild illness experienced by paediatric COVID-19 patients, ailing children were very easily considered to have influenza, especially in the early period of the COVID-19 epidemic, and could not be admitted to the hospital in time. Although the illnesses of most children with COVID-19 were not severe, patients with milder illness and those without symptoms might play an important role in SARS-CoV-2 transmission. It is critical to distinguish COVID-19 from influenza in children. Here, we described the comprehensive clinical characteristics of children with COVID-19 and influenza during the COVID-19 epidemic in Wuhan.
Methods
Study design and participants
A total of 585 paediatric patients, including 248 with confirmed cases of COVID-19, 188 with confirmed cases of influenza A and 149 with confirmed cases of influenza B, from Wuhan Children’s Hospital were retrospectively studied. COVID-19 patients were hospitalized from January 26 to March 23, 2020, and influenza patients were admitted to the hospital from August 8, 2019, to January 26, 2020. All patients with confirmed COVID-19 recruited in this study were diagnosed by SARS-CoV-2 positivity in RT-PCR according to the World Health Organization interim guidance, and patients with confirmed influenza were diagnosed by the presence of IgM antibody against influenza virus A or B. The clinical information, including treatments, discharge dates and length of stay, was monitored up to March 28, 2020.
Data collection
Data on epidemiological information, demographic characteristics, clinical manifestations, laboratory results, treatment measures and discharge date were extracted from electronic medical records. Clinical features consisted of the dates of illness onset and admission, symptoms, coexisting conditions and complications. Laboratory tests included a complete blood count, coagulation parameters, C-reactive protein, serum amyloid protein, procalcitonin, liver and renal function parameters, lactate dehydrogenase, lactate dehydrogenase isoenzyme 1, creatine kinase and creatine kinase isoenzyme 1. Treatment measures included oxygen therapy, antiviral agents, antibacterial agents, corticosteroids, budesonide suspension and immunomodulatory agents. All the clinical data were reviewed by team paediatricians. COVID-19 severity was classified according to experts’ consensus statement for COVID-19 in children [
11]. Patients with asymptomatic cases were defined as children positive for SARS-CoV-2 without manifestations of clinical symptoms or abnormal chest imaging findings. Patients with mild cases were defined as patients who had only fever, cough, pharyngeal pain, nasal congestion, fatigue, headache, myalgia or discomfort but no abnormal radiological findings. Patients with moderate cases were defined as children who had pneumonia on chest CT with or without fever and respiratory symptoms such as cough but did not meet the criteria for severe pneumonia. Patients with severe cases were defined as those who met any of the following criteria: (1) increased respiratory rate: ≥ 70 times/min for those < 1 year of age or ≥ 50 times/min for those ≥ 1 year of age (after ruling out the effects of fever and crying); (2) oxygen saturation < 92%; (3) hypoxia: assisted breathing (moans, nasal flaring, and three-concave sign), cyanosis, or intermittent apnoea; (4) a disturbance of consciousness: somnolence, coma, or convulsion; and (5) food refusal or feeding difficulty, with signs of dehydration. Patients with critical cases met one of the following criteria and required intensive care unit (ICU) care: (1) respiratory failure requiring mechanical ventilation, (2) shock, or (3) other organ failure.
SARS-CoV-2 nucleic acid testing
SARS-CoV-2 nucleic acid testing was performed by the laboratory department of Wuhan Children’s Hospital, and the procedure was the same as that described by Lu et al. [
7]. In brief, nasopharyngeal or throat swabs were tested for the presence of SARS-CoV-2 nucleic acid using real-time reverse transcription polymerase chain reaction (RT-PCR). Viral nucleic acids were extracted with the High Pure Viral Nucleic Acid Kit (Zhongzhi, Wuhan, China). The primers for RT-PCR assays were as follows:
forward primer 5′-TCAGAATGCCAATCTCCCCAAC-3′;
reverse primer 5′-AAAGGTCCACCCGATACATTGA-3′; and.
probe 5′ CY5-CTAGTTACACTAGCCATCCTTACTGC-3′ BHQ1.
Amplifications were performed by incubation at 50 °C for 15 min and 95 °C for 3 min, followed by 45 cycles at 95 °C for 15 s and 60 °C for 30 s.
Statistical analysis
Continuous variables were described as median and interquartile range (IQR) values. The comparison of medians was analysed with the Kruskal-Wallis test. Categorical variables were calculated as the percentages of patients in each category and compared using χ2 or Fisher’s exact tests as appropriate. All statistical analyses were performed in SPSS software version 20.0. Two-sided α values of less than 0.05 indicated statistical significance.
Discussion
As of June 16, 2020, more than 8 million people worldwide have been infected with SARS-CoV-2, including more than 80 thousand people in China. However, approximately one thousand confirmed paediatric SARS-CoV-2 infections have been reported in China [
2], and knowledge of the clinical features of paediatric cases is limited. Here, we comprehensively and comparatively characterized the clinical features of children with COVID-19 and those with influenza A or influenza B in Wuhan during the COVID-19 epidemic.
Our data demonstrated that the epidemiological profiles of paediatric COVID-19 patients were different from those of paediatric influenza patients. The age of children with COVID-19 was older than that of children with influenza. Our analysis showed that 46 (55.46%) influenza A patients and 21 (42.00%) influenza B patients were co-infected with
Mycoplasma, 6 (3.54%) influenza A patients and 9 (7.03%) influenza B patients were co-infected with cytomegalovirus, and 7 (4.12%) influenza A patients and 3 (2.24%) influenza B patients were co-infected with Epstein-Barr virus. The distribution of these common pathogens in influenza patients was identical to that in COVID-19 patients. Few COVID-19 patients were co-infected with influenza. This might indicate that other pathogen infections were independent of SARS-CoV-2 infection. Similar to influenza [
10,
12], SARS-CoV-2 exhibits prevalent human-to-human transmission through close contact; 77.4% of children had a history of household contact, and the remaining (22.6%) COVID-19 patients had an unknown exposure history and might have acquired community infection.
In this study, more than half of the paediatric COVID-19 patients were diagnosed with mild or moderate cases, and 1.61% of cases were severe, which was significantly less than the number of severe influenza cases. Additionally, the severity of COVID-19 in children was obviously different from that in adult patients. Among adult COVID-19 patients, 20 to 25% were admitted to the ICU, 5% had critical cases, and 3 to 4% died [
13‐
15]. This might indicate that the pathogenicity of SARS-CoV-2 in children resembled that of two other severe-respiratory-disease-associated coronaviruses, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), and children with SARS or MERS also suffered much less than adults with these illnesses [
16,
17].
Fever and cough were the predominant symptoms at the onset of illness for both COVID-19 and influenza paediatric patients. Fever was identified in 34.68% of the COVID-19 cases, 70.21% of the influenza A cases and in 74.50% of the influenza B cases. Cough was present in 31.85% of COVID-19 cases, which was more than half of that in influenza cases. Although COVID-19 patients were less likely to exhibit symptoms and signs of respiratory infection, such as fever, cough, chills, sneezing, nasal congestion and rhinorrhoea, but more likely to present gastrointestinal symptoms, including vomiting, diarrhoea, dyspnoea and abdominal pain, it is not easy to differentiate COVID-19 from influenza in children on the basis of symptoms. Therefore, it might be necessary to closely monitor and examine child contacts.
The limitation of this study is that symptom-free children in the COVID-19 group were routinely screened out on the basis of close child contacts, but influenza patients were admitted to the hospital after the appearance of symptoms. This would upwardly bias the divergences of the COVID-19 group from the influenza groups. Another limitation is that COVID-19 patients were diagnosed on the basis of SARS-CoV-2 positivity in RT-PCR, but influenza patients were diagnosed on the basis of the presence of IgM antibody against influenza A virus or influenza B virus, which did not allow the comparison of COVID-19 and influenza cases at similar stages of disease duration. Partial information of the COVID-19 patients in this hospital centre was reported by other groups [
7,
18,
19]. However, we independently described the characteristics of COVID-19 patients from different aspects. In addition, the oxygen saturation level was not detected in every patient. Only patients with moderate, severe and critical cases had oxygen saturation level data; therefore, we did not analyse these data. We could not obtain an accurate duration of oxygen support; therefore, we did not analyse these data or show this information in the tables.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.